SCHEMBL2660844

SCHEMBL2660844

COc1cc(F)ccc1-c1cccc2c(N)c3c(nc12)CN(C1CC1)C3=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY1R P25929 1/20 0.41
▸ NPY5R Q15761 1/20 0.41
▸ UGCG Q16739 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ KCNH2 Q12809 1/20 0.35
▸ CCNT1 O60563 3/20 0.35
▸ CDK9 P50750 3/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ALK Q9UM73 1/20 0.35
▸ PDE4A P27815 4/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ GRIN1 Q05586 2/20 0.33
▸ GRIN2B Q13224 2/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ CASP7 P55210 1/20 0.33
▸ GRM2 Q14416 1/20 0.33
▸ AVPR2 P30518 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919174 0.96 NPY1R (0.40) NPY1RNPY5RUGCGMAPK1CNR2
SCHEMBL2661489 0.93 NPY1R (0.40) NPY1RNPY5RUGCGMAPK1CCNT1
SCHEMBL2657321 0.91 NPY1R (0.40) NPY1RNPY5RUGCGMAPK1PDE4A
SCHEMBL4922297 0.91 NPY1R (0.43) NPY1RNPY5RUGCGMAPK1ADORA2A
SCHEMBL2661576 0.90 CRHR1 (0.41) NPY1RNPY5RPDE4AGABRG2GABRB3
SCHEMBL2669504 0.89 GABRG2 (0.41) NPY1RNPY5RCCNT1CDK9ADORA2A
SCHEMBL2669596 0.88 PDE4A (0.42) MAPK1KCNH2PDE4A
SCHEMBL2661365 0.87 NPY1R (0.40) NPY1RNPY5RMAPK1PDE4AGABRG2
SCHEMBL2661690 0.87 GABRA1 (0.44) NPY1RNPY5RMAPK1ADORA2APDE4A
SCHEMBL4921068 0.87 NPY1R (0.39) NPY1RNPY5RMAPK1KCNH2GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF NPY1R 126/4885NPY5R 104/4885UGCG 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback